We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chewy Stock Falls 24.9% in a Month as Risks Challenge Growth Momentum
Read MoreHide Full Article
Key Takeaways
CHWY shares fell 24.9% in a month as earnings estimates declined 3.6% over the same period.
CHWY's Autoship sales rose 9.3% and accounted for 84.6% of second-quarter net sales.
CHWY trades at 0.53X forward sales, near its five-year low, as margin and demand pressures persist.
Chewy, Inc. (CHWY - Free Report) shares have plunged 24.9% in the past month, sharpening the debate over whether improving operating fundamentals can offset softer consumer demand, margin normalization and weaker estimate momentum.
Image Source: Zacks Investment Research
The pullback has pushed valuation close to a five-year low. Yet recurring Autoship sales, customer growth and expansion in pet health continue to provide operating support, leaving investors to weigh a cheaper entry point against near-term execution risks.
Chewy’s One-Month Slide Resets the Debate
The stock’s 24.9% four-week decline comes with a 3.6% reduction in the current fiscal-year earnings estimate over the same period. That combination adds caution for investors looking for evidence that sentiment and expectations have stabilized.
Chewy’s second-quarter fiscal 2026 results were firmer operationally. Net sales rose 7.3% year over year to $3.33 billion, while adjusted EBITDA increased to $226.7 million. The contrast between business performance and falling estimates makes the reset in market expectations the central issue.
CHWY Growth Drivers Remain Intact
Autoship customer sales increased 9.3% year over year and represented 84.6% of total net sales in the second quarter. Active customers reached 21.7 million, while net sales per active customer rose to $602, supporting the recurring-revenue and engagement story.
Health, pharmacy and newer offerings add growth avenues beyond core retail. Freshpet, Inc. (FRPT - Free Report) also shows that parts of the pet market remain capable of faster expansion, with second-quarter 2026 net sales rising 15.5% to $305.6 million. That performance provides useful context for category demand and competitive intensity.
Chewy Faces Consumer and Margin Pressure
Pressure remains visible in discretionary purchases and premiumization. Treat sales growth slowed more sharply than core food in the second quarter, while management said broader discretionary attachment remained pressured across consumables and hard goods.
Profitability also benefited from items that may not repeat. Roughly $10 million of second-quarter upside came from timing-related benefits, while more than $5 million reflected discrete items. Management expects gross margin to decline modestly sequentially in the third quarter as those benefits normalize.
CHWY Valuation Near a Five-Year Low
CHWY trades at 0.53X forward 12-month sales, only slightly above its five-year low of 0.52X and well below the five-year median of 1.12X. The discount is substantial, but weaker estimates and consumer pressure can keep a low multiple from rerating quickly.
Image Source: Zacks Investment Research
Petco Health and Wellness Company, Inc. (WOOF - Free Report) offers another industry reference point. Petco reported second-quarter 2026 net sales of about $1.5 billion, up 0.05%, while comparable sales increased 0.6%. The mixed peer backdrop reinforces that valuation should be considered alongside each company’s growth, margin and execution profile.
Chewy’s Signals Still Point to Caution
Chewy’s lower valuation and recurring sales base provide support, but the recent share decline, estimate cuts and margin normalization keep the near-term setup unsettled. The key question is whether operating gains can continue while discretionary demand remains soft and temporary profit benefits fade.
CHWY currently carries a Zacks Rank #4 (Sell). It has a Growth Score of A, a Value Score of B, a Momentum Score of C and a VGM Score of A. The favorable growth and value characteristics contrast with weaker near-term earnings-revision signals, underscoring the difference between an inexpensive stock and one whose expectations have fully reset.
View the Zacks #1 Rank List
Image: Bigstock
Chewy Stock Falls 24.9% in a Month as Risks Challenge Growth Momentum
Key Takeaways
Chewy, Inc. (CHWY - Free Report) shares have plunged 24.9% in the past month, sharpening the debate over whether improving operating fundamentals can offset softer consumer demand, margin normalization and weaker estimate momentum.
Image Source: Zacks Investment Research
The pullback has pushed valuation close to a five-year low. Yet recurring Autoship sales, customer growth and expansion in pet health continue to provide operating support, leaving investors to weigh a cheaper entry point against near-term execution risks.
Chewy’s One-Month Slide Resets the Debate
The stock’s 24.9% four-week decline comes with a 3.6% reduction in the current fiscal-year earnings estimate over the same period. That combination adds caution for investors looking for evidence that sentiment and expectations have stabilized.
Chewy’s second-quarter fiscal 2026 results were firmer operationally. Net sales rose 7.3% year over year to $3.33 billion, while adjusted EBITDA increased to $226.7 million. The contrast between business performance and falling estimates makes the reset in market expectations the central issue.
CHWY Growth Drivers Remain Intact
Autoship customer sales increased 9.3% year over year and represented 84.6% of total net sales in the second quarter. Active customers reached 21.7 million, while net sales per active customer rose to $602, supporting the recurring-revenue and engagement story.
Health, pharmacy and newer offerings add growth avenues beyond core retail. Freshpet, Inc. (FRPT - Free Report) also shows that parts of the pet market remain capable of faster expansion, with second-quarter 2026 net sales rising 15.5% to $305.6 million. That performance provides useful context for category demand and competitive intensity.
Chewy Faces Consumer and Margin Pressure
Pressure remains visible in discretionary purchases and premiumization. Treat sales growth slowed more sharply than core food in the second quarter, while management said broader discretionary attachment remained pressured across consumables and hard goods.
Profitability also benefited from items that may not repeat. Roughly $10 million of second-quarter upside came from timing-related benefits, while more than $5 million reflected discrete items. Management expects gross margin to decline modestly sequentially in the third quarter as those benefits normalize.
CHWY Valuation Near a Five-Year Low
CHWY trades at 0.53X forward 12-month sales, only slightly above its five-year low of 0.52X and well below the five-year median of 1.12X. The discount is substantial, but weaker estimates and consumer pressure can keep a low multiple from rerating quickly.
Image Source: Zacks Investment Research
Petco Health and Wellness Company, Inc. (WOOF - Free Report) offers another industry reference point. Petco reported second-quarter 2026 net sales of about $1.5 billion, up 0.05%, while comparable sales increased 0.6%. The mixed peer backdrop reinforces that valuation should be considered alongside each company’s growth, margin and execution profile.
Chewy’s Signals Still Point to Caution
Chewy’s lower valuation and recurring sales base provide support, but the recent share decline, estimate cuts and margin normalization keep the near-term setup unsettled. The key question is whether operating gains can continue while discretionary demand remains soft and temporary profit benefits fade.
CHWY currently carries a Zacks Rank #4 (Sell). It has a Growth Score of A, a Value Score of B, a Momentum Score of C and a VGM Score of A. The favorable growth and value characteristics contrast with weaker near-term earnings-revision signals, underscoring the difference between an inexpensive stock and one whose expectations have fully reset.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.